MAPK1 and neoplasm: Moreover, several enriched pathways have been evidenced to participate in malignant tumor behavior, therapeutic resistance, and clinical outcomes including ribosome biogenesis in eukaryotes,[34, 35] MAPK1/MAPK3 signaling,[36] transcriptional activation by NRF2 in response to phytochemicals,[37] and positive regulation of phosphorylation (Figure S4c,d, Supporting Information).[38] These findings indicate the development of chemotherapy resistance and the underlying biological processes in non‐responder patients.